News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeant Pharmaceuticals International (VRX) Reports 2012 Fourth Quarter Financial Results



2/28/2013 6:49:14 AM

MONTREAL, Nov. 2, 2012 /PRNewswire/ --

•2012 Third Quarter Total Revenue $884 million?Organic growth (same store sales) was approximately 14% ?Pro forma organic growth was approximately 12%
•2012 Third Quarter GAAP EPS $0.02; Cash EPS $1.15
•2012 Third Quarter GAAP Cash Flow from Operations was $167 million; Adjusted Cash Flow from Operations was $241 million

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES